Skip to main content

The pharmacy day | A question to investigate

Growth that fits the pharmacy you actually run

Another service can bring opportunity into an independent pharmacy. It can also take the same pharmacist, room and working capital away from work the business already needs to deliver. The useful question is not simply whether a service has a fee. It is whether a particular pharmacy can deliver it consistently, safely and with a worthwhile contribution after its real demands are understood.

Film credits

In the conversation.

NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.

University of Warwick IATL | AI Ethics NowpharmaphorumTechRadar ProET PharmaFinancial TimesPharmaceutical TechnologyPharmaTimesManufacturing ChemistDigital HealthDaily BusinessTheBusinessDesk.comStartups MagazineInsider MediaYorkshire PostYork PressBusinessCloud

Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.

Begin with the decision on your desk

Perhaps a new service is being considered, opening hours are changing or a consultation room has become the busiest space in the building. Start with one decision and its alternatives: introduce the service, improve an existing pathway, change its timetable or postpone expansion. Each option should have an owner, a review date and a reason it might be rejected. That makes the analysis useful before anyone buys another tool.

Separate income, contribution and cash

NHSBSA publishes payment information and the monthly Drug Tariff (NHSBSA, n.d.). Those are starting references; a published payment does not describe the cost of delivery in your premises. Build a service account that separates earned income, submitted claims and cash received. Then identify incremental staff cover, consumables, equipment, administration and any displaced activity. Allocated overhead can inform longer-term viability, but it should not be confused with the additional cash required for a short trial.

Capacity lives around the whole episode.

A free room is only one condition. Explore the resources that determine whether a pharmacy can deliver a service reliably.

Appropriate demand

Enquiries, bookings and eligible completed episodes are different events. A population estimate or busy counter does not establish demand that the service can appropriately meet.

The useful question

Which requests are suitable, and when do people actually need access?

Observe enquiry outcomes, eligibility through the responsible service and timing. Keep unsuitable routing distinct from failed access.

Public pathway interpretation | NHS England (2026) | Pharmacy prescribing-based service commissioning. No patient records or operational results are shown.

Demand has to survive the journey

A local population estimate is not a booked consultation. A booking is not a completed service, and a completed service is not automatically an accepted claim. Follow the journey in separate steps. For Pharmacy First, use the current service specification to define what belongs within the service before counting opportunities. Include enquiries that do not become consultations so that a busy counter does not get mistaken for commercially usable demand.

A break-even question you can use now

For a service with a positive contribution per eligible completion, divide additional session cost by contribution per completion to estimate the activity needed to cover that session. Use locally verified payment and variable-cost assumptions, then show a range for uncertainty. Keep fixed investment and displaced work outside that simple calculation until they are added explicitly. If contribution per completion is zero or negative, more activity alone does not repair the case.

Would another session actually help?

Space, professional cover and follow-through have to meet in the same operating window. Examine the constraint before investing.

An independent owner is choosing between adding a service session, changing an existing timetable and delaying expansion. Each option uses the same finite professional cover. The question is whether observed appropriate demand and delivery contribution justify the additional session cost.

Distinguishes an empty room from usable service capacity and shows why a purchase may fail to resolve the real constraint.

What would we need to understand?

  • Requests and appropriate service routes by session
  • Actual professional cover and support availability
  • Usable room and equipment states
  • Preparation, documentation and follow-up effort

Constructed decision example | No customer results are shown.

NHSBSA (n.d.) | NHS England (n.d.)

A first evaluation small enough to learn from

A proposed PHARMORIS evaluation could examine one service in one pharmacy over an agreed baseline and observation period. The owner would supply authorised aggregate activity, staff time estimates and actual service costs. Compare the proposed timetable with the current arrangement, recording any changes in opening hours or staffing. The output would be an inspectable decision brief, with assumptions visible and the calculations reproducible, rather than a promise that the service should expand.

What would make the result convincing?

Agree the success threshold before collecting results. Useful measures include completed eligible activity, claim acceptance, staff minutes per completion, delayed routine work and incremental contribution. Review variation by session rather than relying on a single monthly average. If performance depends on unpaid owner overtime, show it explicitly. If the result improves only because demand was diverted from another service, count that displacement before attributing value to the new arrangement.

Know when to stop or redesign

A trial should pause if safe cover is not maintained, the required data cannot be reconciled or the additional workload exceeds the agreed limit. Weak demand may call for a different timetable rather than more marketing. A positive commercial signal still needs a separate review of service quality and professional requirements. PHARMORIS is being developed to help organise this reasoning; it is not a substitute for the owner's judgement or the pharmacist's accountability.

NEUVIOR Data Analysis

A source.
A question.
A clearer decision.

Useful intelligence keeps its evidence attached.

Our public analysis connects a defined question with named sources, reporting periods and methods. Each source below shows the work available today and the access still needed.

Published-data analysis, research hypotheses and evidence studies are distinct kinds of work. Their meaning should remain clear as the programme grows.

NHS Business Services Authority | Annual

Prescription Cost Analysis

How does activity differ from ingredient-cost concentration?

Analysis available

Official source

NHS Business Services Authority | Monthly

English Prescribing Dataset with SNOMED Code

Which product and organisational patterns merit a closer investigation?

Metadata retrieved

Official source

Medicines and Healthcare products Regulatory Agency | Event-driven; monthly roundup also published

Medicines and device safety communications

Which official communication should a responsible team read next?

Snapshot retrieved

Official source

NHS Business Services Authority and NHS England | Weekly

Dictionary of medicines and devices

Can the same product identity be followed consistently across sources?

Access review

Official source

Explore NEUVIOR Data Analysis

Bring a real choice to the conversation

The strongest starting material is a decision you could make within the next operating cycle, the two options you are considering and the constraint you cannot ignore. A modest pharmacy does not need a corporate transformation programme to learn something valuable. It needs a clear question, a fair comparison and a result that tells the owner what to do next, including when the most sensible answer is to wait.

Another useful angle.

NEWSPerspectives & features